Taysha Gene Therapies Quarterly Income Statement
NASDAQ: TSHAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Taysha Gene Therapies revenue and earnings
In the quarter ended Jun 30, 2026, Taysha Gene Therapies generated $0 in revenue, down 100.0% from the same quarter a year earlier. Taysha Gene Therapies reported a net loss of $46.6 million, compared with a loss of $26.9 million a year earlier. Diluted earnings per share came in at -$0.13.
Summary generated from market data by MetaCap's automated system. Methodology
Taysha Gene Therapies income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 5.49M | 0 | 1.99M | 2.30M | 2.02M | 1.79M | 1.11M | 3.41M | 3.60M | 4.75M |
| Revenue growth (YoY) | -100.00% | -100.00% | +171.27% | -100.00% | +78.60% | -32.51% | -43.90% | -62.33% | -53.57% | -27.52% | — | — |
| Operating Expenses | 47.35M | 43.49M | 33.78M | 34.02M | 28.74M | 23.72M | 21.95M | 27.69M | 22.41M | 27.74M | 19.85M | 21.00M |
| Research & Development | 38.64M | 33.81M | 24.95M | 25.75M | 20.14M | 15.56M | 15.32M | 14.95M | 15.07M | 20.66M | 12.68M | 11.79M |
| Operating Income | -47.35M | -43.49M | -28.30M | -34.02M | -26.75M | -21.42M | -19.93M | -25.90M | -21.30M | -24.33M | -16.25M | -16.25M |
| Interest Expense | 6.00K | 9.00K | 12.00K | 15.00K | 17.00K | 19.00K | 22.00K | 24.00K | 27.00K | 29.00K | 713.00K | 1.47M |
| Other Income (Expense) | 710.00K | 1.08M | 449.00K | 1.29M | -129.00K | -108.00K | 1.15M | 374.00K | 371.00K | 269.00K | 63.99M | -100.84M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -46.64M | -42.41M | -27.85M | -32.73M | -26.88M | -21.53M | -18.79M | -25.52M | -20.93M | -24.06M | 47.74M | -117.09M |
| Net Income growth (YoY) | — | — | — | — | — | — | -139.35% | — | — | — | — | — |
| EPS (Basic) | -0.13 | -0.12 | -0.08 | -0.09 | -0.09 | -0.08 | -0.07 | -0.10 | -0.09 | -0.10 | 0.63 | -0.93 |
| EPS (Diluted) | -0.13 | -0.12 | -0.08 | -0.09 | -0.09 | -0.08 | -0.07 | -0.10 | -0.09 | -0.10 | 0.63 | -0.93 |
| Shares Outstanding (Basic) | 369.04M | 366.63M | — | 353.31M | 297.99M | 269.31M | — | 267.82M | 232.82M | 231.25M | — | 125.70M |
| Shares Outstanding (Diluted) | 369.04M | 366.63M | — | 353.31M | 297.99M | 269.31M | — | 267.82M | 232.82M | 231.25M | — | 125.70M |
| EBITDA | -46.95M | -43.19M | -28.00M | -33.82M | -26.45M | -21.14M | -19.63M | -25.60M | -21.00M | -24.00M | -15.88M | -15.95M |
| Operating Margin | — | — | -515.95% | — | -1347.08% | -930.54% | -985.76% | -1448.43% | -1915.38% | -713.28% | -450.78% | -342.39% |
| Net Margin | — | — | -507.77% | — | -1353.58% | -935.23% | -929.03% | -1427.52% | -1882.01% | -705.39% | 1324.67% | -2467.07% |
This table shows 12 quarterly periods of Taysha Gene Therapies's income statement, from Q2 2026 back to Q3 2023, across 15 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow TSHA's reporting calendar. What is a income statement?